CORRECTION: Aytu BioPharma to Present at Upcoming September Investor Conferences
(This release corrects the previous one that was issued on September 7, 2021 to reflect the time of the Cantor...
News
Novamind Opens 6th Integrative Psychiatry Clinic, Adds 3rd Clinical Research Site
TORONTO, ON / ACCESSWIRE / September 30, 2021 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health...
Love Pharma, Inc., Formerly Glenbriar Technologies, Inc., Announces Name Change, Consolidation, and Acquisition of Kick Pharmaceuticals, Inc
VANCOUVER, BC / ACCESSWIRE / September 30, 2021 / Love Pharma Inc. (CSE:LUV) (the "Company") announces that it has changed...
Lankenau Heart Institute, part of Main Line Health, first in North America to sign long-term strategic partnership with Philips utilizing integrated cardiovascular solutions
Lankenau Heart Institute, part of Main Line Health Case review at Lankenau Heart Institute September 30, 2021 Unique five-year agreement...
Summit Therapeutics Presents Further Breakthrough Insights Surrounding the Novel Mechanism of Action for its Investigational Drug Ridinilazole During IDWeek 2021
Cambridge, Massachusetts, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit” or the “Company”) is today displaying...
SPO Global Inc. (OTC Pink: SPOM) Provides a Shareholder Update
Shandong, China, Sept. 30, 2021 (GLOBE NEWSWIRE) -- CEO Lu Fengyu of SPO Global Inc. (OTC Pink: SPOM) met Mr....
Anika Launches the WristMotion® Total Wrist Arthroplasty System at the American Society for Surgery of the Hand Annual Meeting
Designed to preserve natural motion and maximize stability, the WristMotion® Total Wrist Arthroplasty System provides an advanced solution for wrist...
Antares Pharma Initiates Phase I Study For ATRS-1902 For Adrenal Crisis Rescue
Pharmacokinetic data results expected in 1Q 2022EWING, N.J., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the...
Genetic Technologies Limited Interview to Air on Bloomberg TV (U.S.) on the RedChip Money Report®
MELBOURNE, Australia, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in...
Celsion to Present at Three Investment Conferences in October
LAWRENCEVILLE, N.J., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and...
Allied Corp Announces Approval of Research and Plant Breeding License for Psychoactive and Non-Psychoactive Cannabis in Colombia
KELOWNA, British Columbia, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Allied Corp. ("Allied" or the “Company”) (OTCQB: ALID) is pleased to...
Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Leading Next Wave of Psychedelic Drug Development
NEW YORK, Sept. 30, 2021 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) announces the availability of...
Assure to Attend Investor Conferences in October 2021
DENVER, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the “Company” or “Assure”) (NASDAQ: IONM; TSXV: IOM), a provider...
New, late-breaking data at EADV highlights emerging clinical profile of amlitelimab (formerly KY1005) in adults with inadequately controlled moderate-to-severe atopic dermatitis
New, late-breaking data at EADV highlights emerging clinical profile of amlitelimab (formerly KY1005) in adults with inadequately controlled moderate-to-severe atopic...
New Data Highlighting Itch Reduction with Topical Roflumilast in Multiple Dermatologic Conditions Presented at European Academy of Dermatology and Venereology Congress
Topical roflumilast provided significant improvements in severity and burden of itch in Phase 3 plaque psoriasis studies, as well as...
180 Life Sciences Corp. Continues To Expand Intellectual Property Portfolio
Notice of Allowance Issued for “Method for Reducing Post-Operative Cognitive Dysfunction (POCD)”PALO ALTO, Calif., Sept. 30, 2021 (GLOBE NEWSWIRE) --...
Minerva Neurosciences Announces Study Results Demonstrating Bioequivalence of Phase 2b, Phase 3, and Planned Commercial Formulations of Roluperidone for Treatment of Negative Symptoms of Schizophrenia
Company to Request Pre-NDA Meeting with U.S. Food and Drug Administration Figure 1 Comparisons of AUCinf and Cmax between Phase...
Mustang Bio to Participate in Chardan’s Virtual 5th Annual Genetic Medicines Conference
WORCESTER, Mass., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on...
Ambu A/S: Financial calendar
This financial calendar lists the expected dates of publication of financial announcements and the Annual General Meeting for the financial...
Viridian Therapeutics to Present Preclinical Data on VRDN-001 and VRDN-002 at the 90th Annual Meeting of the American Thyroid Association
WALTHAM, Mass., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company advancing new treatments for...